Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.50 |
| ▸ | CCR3 | P51677 | 4/20 | 0.47 |
| ▸ | CCR1 | P32246 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MYD88 | Q99836 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | EIF4E | P06730 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2209757 | 0.86 | CCR3 (0.62) | MCHR1CCR3CCR1ALDH1A1MAPT | |
| SCHEMBL2213758 | 0.78 | CCR3 (0.63) | MCHR1CCR3CCR1ALDH1A1MAPT | |
| SCHEMBL6111519 | 0.78 | MCHR1 (0.46) | MCHR1CCR3CCR1ALDH1A1SIGMAR1 | |
| SCHEMBL12511802 | 0.76 | CCR3 (0.58) | MCHR1CCR3CCR1MAPTSIGMAR1 | |
| SCHEMBL6753069 | 0.76 | CCR3 (0.62) | MCHR1CCR3CCR1ALDH1A1MAPT | |
| SCHEMBL12511839 | 0.76 | CCR3 (0.59) | MCHR1CCR3CCR1MAPTSIGMAR1 | |
| SCHEMBL2214242 | 0.76 | CCR3 (0.52) | MCHR1CCR3CCR1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL2210887 | 0.75 | CCR3 (0.59) | MCHR1CCR3CCR1MAPTSIGMAR1 | |
| SCHEMBL2212794 | 0.75 | CCR3 (0.59) | MCHR1CCR3CCR1ALDH1A1MAPT | |
| SCHEMBL2212823 | 0.75 | CCR3 (0.63) | MCHR1CCR3CCR1SIGMAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389616-B1 | 3,4-Dihalobenzylpiperidine derivatives and their medical use | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-7115635-B2 | Benzylpiperidine compound | MITSUBISHI PHARMA CORPORATION (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | MITSUBISHI PHARMA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1389616-A1 | NOVEL BENZYLPIPERIDINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | CCL2, CXCR1, CCR5 | MCHR1 1048/4885CCR3 21/4885CCR1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.